Thromboembolism, cancer, and oral contraceptives.
D000293:Adolescent; D000328:Adult; D000818:Animals; D001943:Breast Neoplasms / Q000139:chemically induced; D002561:Cerebrovascular Disorders / Q000139:chemically induced; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004739:England; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced; D009369:Neoplasms / Q000139:chemically induced*; D011230:Precancerous Conditions; D011247:Pregnancy; D011336:Probability; D011655:Pulmonary Embolism / Q000139:chemically induced; D012189:Retrospective Studies; D013548:Sweden; D013923:Thromboembolism / Q000139:chemically induced*; D013924:Thrombophlebitis / Q000139:chemically induced; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced
D003276:Contraceptives, Oral; D004967:Estrogens